

Pierre Aman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3105367/publications.pdf>

Version: 2024-02-01

53
papers

3,571
citations

257450

24
h-index

214800

47
g-index

53
all docs

53
docs citations

53
times ranked

3849
citing authors

#	ARTICLE	IF	CITATIONS
1	Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. <i>Nature</i> , 1993, 363, 640-644.	27.8	859
2	Rearrangement of the transcription factor gene <i>CHOP</i> in myxoid liposarcomas with t(12;16)(q13;p11). <i>Genes Chromosomes and Cancer</i> , 1992, 5, 278-285.	2.8	284
3	The multifunctional FUS, EWS and TAF15 proto-oncoproteins show cell type-specific expression patterns and involvement in cell spreading and stress response. <i>BMC Cell Biology</i> , 2008, 9, 37.	3.0	284
4	The macrophage migration inhibitory factor MIF is a phenylpyruvate tautomerase. <i>FEBS Letters</i> , 1997, 417, 85-88.	2.8	227
5	Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 449-457.	4.1	160
6	Cell Cycle and Cell Size Dependent Gene Expression Reveals Distinct Subpopulations at Single-Cell Level. <i>Frontiers in Genetics</i> , 2017, 8, 1.	2.3	149
7	Expression Patterns of the Human Sarcoma-Associated Genes FUS and EWS and the Genomic Structure of FUS. <i>Genomics</i> , 1996, 37, 1-8.	2.9	144
8	Fusion of the FUS gene with ERG in acute myeloid leukemia with t(16;21)(p11;q22). <i>Genes Chromosomes and Cancer</i> , 1994, 11, 256-262.	2.8	116
9	Cytogenetic and molecular genetic analyses of liposarcoma and its soft tissue simulators: recognition of new variants and differential diagnosis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2001, 439, 141-151.	2.8	101
10	Fusion genes in solid tumors. <i>Seminars in Cancer Biology</i> , 1999, 9, 303-318.	9.6	95
11	The Myxoid/Round Cell Liposarcoma Fusion Oncogene FUS-DDIT3 and the Normal DDIT3 Induce a Liposarcoma Phenotype in Transfected Human Fibrosarcoma Cells. <i>American Journal of Pathology</i> , 2006, 168, 1642-1653.	3.8	91
12	Distinct Cytoplasmic and Nuclear Functions of the Stress Induced Protein DDIT3/CHOP/GADD153. <i>PLoS ONE</i> , 2012, 7, e33208.	2.5	87
13	Identification of genes differentially expressed in TLS-CHOP carrying myxoid liposarcomas. , 1999, 83, 30-33.		64
14	Irradiation of myxoid/round cell liposarcoma induces volume reduction and lipoma-like morphology. <i>Acta Oncologica</i> , 2007, 46, 838-845.	1.8	58
15	Cloning and sequencing of a cDNA encoding rat d-dopachrome tautomerase. <i>FEBS Letters</i> , 1995, 373, 203-206.	2.8	52
16	JAK-STAT signalling controls cancer stem cell properties including chemotherapy resistance in myxoid liposarcoma. <i>International Journal of Cancer</i> , 2019, 145, 435-449.	5.1	52
17	FET family fusion oncoproteins target the SWI / SNF chromatin remodeling complex. <i>EMBO Reports</i> , 2019, 20, .	4.5	52
18	Myxoid liposarcoma FUS-DDIT3 fusion oncogene induces C/EBP β -mediated interleukin 6 expression. <i>International Journal of Cancer</i> , 2005, 115, 556-560.	5.1	44

#	ARTICLE	IF	CITATIONS
19	Characterization of the 12q amplicons by high-resolution, oligonucleotide array CGH and expression analyses of a novel liposarcoma cell line. <i>Cancer Letters</i> , 2008, 260, 37-47.	7.2	40
20	FUS-DDIT3 Fusion Protein-Driven IGF-1R Signaling is a Therapeutic Target in Myxoid Liposarcoma. <i>Clinical Cancer Research</i> , 2017, 23, 6227-6238.	7.0	40
21	A methylation PCR approach for detection of fragile X syndrome. , 1999, 14, 71-79.		39
22	Variable FHIT transcripts in non-neoplastic tissues. <i>Genes Chromosomes and Cancer</i> , 1997, 19, 215-219.	2.8	38
23	Duplication of chromosome segment 12q15-24 is associated with atypical lipomatous tumors. A report of the CHAMP collaborative study group. , 1996, 67, 632-635.		34
24	A conserved N-terminal motif is required for complex formation between FUS, EWSR1, TAF15 and their oncogenic fusion proteins. <i>FASEB Journal</i> , 2013, 27, 4965-4974.	0.5	34
25	IGF2/IGF1R Signaling as a Therapeutic Target in MYB-Positive Adenoid Cystic Carcinomas and Other Fusion Gene-Driven Tumors. <i>Cells</i> , 2019, 8, 913.	4.1	32
26	Fusion oncogenes in tumor development. <i>Seminars in Cancer Biology</i> , 2005, 15, 236-243.	9.6	31
27	Phosphatidylinositol-3-kinase (PI3K)/Akt Signaling is Functionally Essential in Myxoid Liposarcoma. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 834-844.	4.1	28
28	The myxoid liposarcoma specific TLS-CHOP fusion protein localizes to nuclear structures distinct from PML nuclear bodies. <i>International Journal of Cancer</i> , 2002, 97, 446-450.	5.1	27
29	Genomic PCR detects tumor cells in peripheral blood from patients with myxoid liposarcoma. , 1996, 17, 102-107.		25
30	Requirement for YAP1 signaling in myxoid liposarcoma. <i>EMBO Molecular Medicine</i> , 2019, 11, .	6.9	25
31	Temperature-Dependent Localization of TLS-CHOP to Splicing Factor Compartments. <i>Experimental Cell Research</i> , 2002, 278, 125-132.	2.6	20
32	Normal and Functional TP53 in Genetically Stable Myxoid/Round Cell Liposarcoma. <i>PLoS ONE</i> , 2014, 9, e113110.	2.5	19
33	Src inhibition represents a potential therapeutic strategy in liposarcoma. <i>International Journal of Cancer</i> , 2015, 137, 2578-2588.	5.1	18
34	Prevalence of the Hippo Effectors YAP1/TAZ in Tumors of Soft Tissue and Bone. <i>Scientific Reports</i> , 2019, 9, 19704.	3.3	18
35	Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation. <i>Laboratory Investigation</i> , 2016, 96, 885-894.	3.7	17
36	The 12q13-q15 translocation breakpoints in pleomorphic adenoma and clear-cell sarcoma of tendons and aponeuroses are different from that in myxoid liposarcoma. <i>Genes Chromosomes and Cancer</i> , 1993, 7, 178-180.	2.8	15

#	ARTICLE	IF	CITATIONS
37	Fusion protein-driven IGF-IR/PI3K/AKT signals deregulate Hippo pathway promoting oncogenic cooperation of YAP1 and FUS-DDIT3 in myxoid liposarcoma. <i>Oncogenesis</i> , 2022, 11, 20.	4.9	14
38	Regulatory mechanisms, expression levels and proliferation effects of the <i>FUS—DDIT3</i> fusion oncogene in liposarcoma. <i>Journal of Pathology</i> , 2016, 238, 689-699.	4.5	13
39	HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death<i>in vitro</i>and<i>in vivo</i>. <i>Oncotarget</i> , 2016, 7, 433-445.	1.8	12
40	Abnormal expression of cell cycle regulators in FUS-CHOP carrying liposarcomas. <i>International Journal of Oncology</i> , 2004, 25, 1349-55.	3.3	12
41	FET fusion oncoproteins interact with BRD4 and SWI/SNF chromatin remodelling complex subtypes in sarcoma. <i>Molecular Oncology</i> , 2022, 16, 2470-2495.	4.6	12
42	Cell Senescence in Myxoid/Round Cell Liposarcoma. <i>Sarcoma</i> , 2014, 2014, 1-7.	1.3	11
43	DDIT3 Expression in Liposarcoma Development. <i>Sarcoma</i> , 2014, 2014, 1-6.	1.3	11
44	Fused in sarcoma (FUS) interacts with the cytolinker protein plectin: Implications for FUS subcellular localization and function. <i>Experimental Cell Research</i> , 2012, 318, 653-661.	2.6	9
45	Hsp90 inhibition by ALIY922 as an effective treatment strategy against myxoid liposarcoma. <i>Cancer Letters</i> , 2015, 367, 147-156.	7.2	9
46	HR23b expression is a potential predictive biomarker for HDAC inhibitor treatment in mesenchymal tumours and is associated with response to vorinostat. <i>Journal of Pathology: Clinical Research</i> , 2016, 2, 59-71.	3.0	9
47	Mapping of the 19p13 breakpoint in an ovarian carcinoma between theINSR andTCF3 Loci. <i>Genes Chromosomes and Cancer</i> , 1993, 8, 134-136.	2.8	8
48	A novel PCR-based approach for the detection of the Huntington disease associated trinucleotide repeat expansion. , 1999, 13, 232-236.		8
49	Total mRNA Quantification in Single Cells: Sarcoma Cell Heterogeneity. <i>Cells</i> , 2020, 9, 759.	4.1	7
50	FUS-DDIT3 Fusion Oncoprotein Expression Affects JAK-STAT Signaling in Myxoid Liposarcoma. <i>Frontiers in Oncology</i> , 2022, 12, 816894.	2.8	7
51	Identification of inhibitors regulating cell proliferation and FUS-DDIT3 expression in myxoid liposarcoma using combined DNA, mRNA, and protein analyses. <i>Laboratory Investigation</i> , 2018, 98, 957-967.	3.7	6
52	Different HSP90 Inhibitors Exert Divergent Effect on Myxoid Liposarcoma In Vitro and In Vivo. <i>Biomedicines</i> , 2022, 10, 624.	3.2	3
53	Fusion Oncogenes of Sarcomas. , 2015, , 321-331.		1